CAS: 781652-57-1 - 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
Formula:C23H16N4O
InChI:InChI=1S/C23H16N4O/c24-16-17-8-7-11-19(14-17)23(28)25-22-15-21(18-9-3-1-4-10-18)26-27(22)20-12-5-2-6-13-20/h1-15H,(H,25,28)
InChI key:InChIKey=BKUIZWILNWHFHD-UHFFFAOYSA-N
SMILES:N#CC1=CC=CC(=C1)C(=O)NC2=CC(=NN2C=3C=CC=CC3)C=4C=CC=CC4
- Synonyms:
- 3-Cyano-N-(2,5-diphenyl-2H-pyrazol-3-yl)-benzamide
- 3-Cyano-N-(2,5-diphenylpyrazol-3-yl)benzamide
- Benzamide, 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)-
- Cdppb
- 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
3-CYANO-N-(1,3-DIPHENYL-1H-PYRAZOL-5-YL)BENZAMIDE
CAS:781652-57-1
Formula:
C23H16N4O
Purity:
97%
Color and Shape:
Solid
Molecular weight:
364.3993
Ref: IN-DA0054PX
1g | To inquire | ||
100mg | 214.00 € | ||
250mg | 592.00 € |
Estimated delivery in United States, on Tuesday 21 Jan 2025
CDPPB
CAS:781652-57-1
CDPPB is a modulator of mGluR5 positive allosteric(with an EC50 of 27 nM in Chinese …
Formula:
C23H16N4O
Purity:
99.16%
Color and Shape:
Solid
Molecular weight:
364.4
Ref: TM-T22641
1mg | 45.00 € | ||
2mg | 59.00 € | ||
5mg | 87.00 € | ||
10mg | 139.00 € | ||
25mg | 243.00 € | ||
50mg | 410.00 € | ||
100mg | 613.00 € |
Estimated delivery in United States, on Monday 27 Jan 2025
3-Cyano-N-(1,3-Diphenyl-1H-Pyrazol-5-Yl)Benzamide
CAS:781652-57-1
Purity:
97%
Molecular weight:
364.40g/mol
Ref: 54-OR1010965
100mg | 149.00 € | ||
250mg | 276.00 € |
Estimated delivery in United States, on Monday 27 Jan 2025
mGluR5 Ligand, CDPPB
CAS:781652-57-1
CDPPB is a potent, selective, and orally active mGluR5 ligand. It has been shown to …
Formula:
C23H16N4O
Purity:
Min. 95%
Molecular weight:
364.4 g/mol
Ref: 3D-GGB65257
25mg | 746.00 € | ||
50mg | 1,124.00 € | ||
100mg | 1,563.00 € |
Estimated delivery in United States, on Monday 3 Mar 2025
CDPPB
CAS:781652-57-1
Applications CDPPB is a glutamate metabotropic (mGluR5) positive allosteric modulator, used in the treatment of …
Formula:
C23H16N4O
Color and Shape:
White to Off-White Solid
Molecular weight:
364.40
Ref: TR-C228800
10mg | Discontinued | Request information |